Aimmune Therapeutics, Inc. announced the membership of its Scientific Advisory Board, comprised of internationally recognized food allergy experts including Dr. Kirsten Beyer, Dr. A. Wesley Burks, Dr. Thomas Casale, Dr. Jonathan Hourihane and Dr. Stacie Jones. All of the members of Aimmune’s Scientific Advisory Board are investigators in PALISADE, Aimmune’s current Phase 3 clinical trial of AR101 for the treatment of peanut allergy. AR101 is Aimmune’s biologic oral immunotherapy for desensitization of patients with peanut allergy.